REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Why now
Thesis: Gene therapy durability data supports ophthalmology pipeline narrative
Catalyst to watch: Regulatory filing or pivotal trial update
Main risk: Early-stage data, no approval or revenue path
Why it matters
Positive three-year durability data for a gene therapy in diabetic retinopathy supports the clinical case, though no regulatory or commercial timeline is given.
Details
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course...
Sources
- prnewswire · 2026-09-24 23:17 UTC